Table 1.1: Total health expenditure as a proportion of GDP in the seven major pharmaceutical markets, 1991-2000
Table 1.2: Total expenditure on pharmaceuticals and other medical non-durables as a proportion of total health expenditure, 1991-2000
Table 2.3: Future pricing scenarios in the US
Table 3.4: Co-payments for drugs/services in Japan, 2002
Table 3.5: Future pricing scenarios in Japan
Table 4.6: European cost containment measures, 2002
Table 4.7: Future pricing scenarios in Europe
Table 5.8: Reimbursement levels of drugs for major diseases in six major markets, 2001
Table 7.9: Relative reimbursement status, price, prescription rates and sales of Taxol (paclitaxel), 2000
Table 7.10: Relative reimbursement status, price, prescription rates and sales of Aricept (donepezil), 2000
Table 7.11: Relative reimbursement status, price, prescription rates and sales of Imigran (somatriptan), 2000
Table 7.12: Relative reimbursement status, price, prescription rates and sales of Zocor (simvastatin), 2000
Table 7.13: Relative reimbursement status, price, prescription rates and sales of Lipitor (atorvastatin), 2000
Table 7.14: Relative reimbursement status, price, prescription rates and sales of Canesten (clotrimazole), 2000
Table 7.15: Relative reimbursement status, price, prescription rates and sales of Amoxil (amoxicillin), 2000
Figure 1.1: Total health expenditure as a proportion of GDP in the seven major pharmaceutical markets, 1991-2000
Figure 1.2: Total expenditure on pharmaceuticals and other medical non-durables as a proportion of total health expenditure, 1991-2000
Figure 1.3: European drug index – ex-factory prices, 1986–1999
Figure 1.4: Drivers and resistors of pharmacoeconomics
Figure 1.5: Pharmaceutical product differentiation versus patient base matrix
Figure 2.6: Drivers and resistors of parallel importing into the US
Figure 4.7: External reference pricing in Europe, 2002
Figure 4.8: The NICE appraisal cycle
Figure 5.9: Comparative summary of reimbursement and average price levels in the seven major markets, 2002
Figure 5.10: Average reimbursement levels of drugs for major diseases across six major markets, 2001
Figure 5.11: Price demand and response curves
Figure 5.12: Market share and revenue impact of reimbursement and formulary status
Figure 5.13: Global pricing and the interaction between country markets
Figure 6.14: Strategic pricing and marketing options for pharmaceutical companies in different pricing and reimbursement scenarios
Figure 6.15: Strategies to maximize revenues and profits in a reference pricing environment
Figure 6.16: Improving pricing negotiations through R&D
Figure 6.17: The pricing pill - improving pricing negotiating through demonstrating product value
Figure 6.18: Cost-benefit analysis of different strategies to maximize revenue in a reference pricing environment
Figure 6.19: Maximizing returns through European launch order in a reference pricing environment
Figure 7.20: Case studies by product differentiation versus patient base
Figure 7.21: Relationship between price, prescription rates and sales of Taxol (paclitaxel), 2000
Figure 7.22: Relationship between price, prescription rates and sales of Aricept (donepezil), 2000
Figure 7.23: Relationship between price, prescription rates and sales of Imigran (somatriptan), 2000
Figure 7.24: Relationship between price, prescription rates and sales of Zocor (simvastatin), 2000
Figure 7.25: Relationship between price, prescription rates and sales of Lipitor (atorvastatin), 2000
Figure 7.26: Relationship between price, prescription rates and sales of Canesten (clotrimazole), 2000
Figure 7.27: Relationship between price, prescription rates and sales of Amoxil (amoxicillin), 2000
[Tabellenverzeichnis ausblenden]
